Tension is building in the life sciences industry as companies are asked to do more with less, while balancing efficiency and resilience.
In the U.S., healthcare costs are rising faster than the economy, putting pressure on pricing and reimbursement [1]. Investors are pushing for faster returns on R&D. All of this is happening as regulatory and public scrutiny intensifies.
The natural reaction is to make cuts and automate processes as quickly as possible. With technology seen as a commodity that requires aggressive short-term cost-cutting, sometimes an organization optimizes so hard it loses its ability to absorb shocks. A critical supplier delay or regulatory change in a market can undo many months of efficiency gains in weeks.
As we move into 2027, this tension will only rise. The main challenge for the life sciences industry will be building efficiency and resilience while trying to establish and maintain a balance between the two.
How to work toward the efficiency/resilience balance in 2027
Here are five things life sciences companies can do in 2027 to address the industry pressure and create a balance between efficiency and resilience:
- Protect your margins. The pricing and reimbursement pressure will continue to rise. Starting January 1, 2027, Medicare’s negotiated prices take effect for drugs, including Ozempic and Wegovy [2]. Companies will need to find savings in operations and overhead so they can keep investing in the pipeline.
- Demonstrate clinical value earlier and more consistently. The faster a product is approved by regulators and delivered to market, the higher the overall return will be on R&D investment. Tools like AI and machine learning models can analyze clinical trial data alongside statistical analysis to confirm results. This way, speed and evidence quality improve at the same time.
- Regionalize critical supply. We’ve seen how shipping delays and trade disruptions can break supply chains that rely on a single source in one region. The safeguard is to regionalize critical materials and production. Build enough redundancy that one disruption won’t stop a therapy from reaching patients.
- Maintain product-level regulatory readiness. Each market sets its own rules for labeling, documentation and manufacturing, and those rules are diverging as trade policy and geopolitics shift. Make sure to have each product’s registrations, labels and supplier records current for every market where it’s sold. When one country changes its requirements, the team can update that product quickly.
- Build in traceability. When an issue occurs, strong traceability enables a quick, targeted response. It also limits the scope and cost of any recall. This applies to raw materials, the disposal of production waste and the continuous monitoring of suppliers, batches and quality flags.
Where AI fits in
AI is going to play a part in all five areas listed above. But to make an organization both more efficient and resilient at the same time, AI adoption must follow these principles:
- Data readiness. AI initiatives require better data quality, collection and governance. Too often, companies don’t do the underlying prep work to cleanse the data they already have. If you want to get the most out of AI, you need to invest in clean, accessible data for it to use. That same data foundation is what makes traceability and regulatory readiness possible.
- Humans-in-the-loop. In life sciences operations, human-in-the-loop checkpoints will continue to be an integral part of quality management and verification. Humans still need to be accountable for AI output. This protects patient safety, drug and device efficacy and product quality throughout the clinical, lab, manufacturing and distribution process. I expect the most widespread uses of AI to be practical tasks like drafting documentation and AI agents taking on routine data review.
- ROI measured in time-to-patient. I expect that leaders will increasingly judge AI investments by how much faster a product reaches regulatory approval or the market itself. Examples include applying AI to discover and confirm new molecules more quickly, or to analyze and report clinical results faster.
Keeping patients at the center
Looking ahead, one risk I see is that the life sciences industry could become overly focused on AI for the sake of AI, and lose sight of the tight human involvement that sparks innovation and drives the team’s vision and science forward. You can’t put the AI “brass ring” ahead of the strong leadership guiding the way and ensuring AI supports delivery of safe patient outcomes and running a healthy business.
For example, when companies decide where to build a plant, they now have to factor in what McKinsey calls a “resilience premium” on top of labor and running costs [3]. The premium is the extra cost they will pay for a secure supply chain and faster time to market. To balance that out, efficiency is needed to protect margins and fund the pipeline.
Efficiency and resilience should be seen as one strategy. Invest in clean, accessible data, keep qualified people accountable for decisions and measure success by how fast you can deliver safe, effective products to patients. AI can help improve each of these things.
Author Bio















